Ann-Lii Cheng, MD, discusses where the of hepatocellular carcinoma is headed.
Ann-Lii Cheng, MD, distinguished professor in the Department of Internal Medicine, director at Graduate Institute of Oncology, and director, Department of Medical Oncology, National Taiwan University College of Medicine, discusses where the of hepatocellular carcinoma (HCC) is headed.
For the past 10 years, Cheng says the responses have really hit the ceiling in terms of monotherapy. About 15% to 20% of patients with HCC respond to monotherapies, meaning 75% to 80% of patients do not have a response.
SELECT Trial Establishes Lenvatinib’s Role in RAI-Refractory DTC
May 2nd 2024In an interview with Targeted Oncology, Lori J. Wirth, MD, delved into how the data from SELECT signals lenvatinib effectiveness as a frontline therapy for patients with RAI-refractory differentiated thyroid cancer.
Read More